Yüklüyor......
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
Despite therapeutic advances, the effective treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains a major clinical challenge. Evasion of apoptosis through upregulating antiapoptotic B-cell lymphoma-2 (BCL-2) family members and p53 inactivation, and abnormal activation of...
Kaydedildi:
| Yayımlandı: | Oncol Res |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Cognizant Communication Corporation
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7851508/ https://ncbi.nlm.nih.gov/pubmed/32093809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504020X15825405463920 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|